Oncotype DX Breast Recurrence Score is a prognostic and predictive assay of 21 genes, initially designed for therapy planning in patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, lymph node-negative or node-positive (maximum 3 nodes involved), early-stage breast cancer. The 9-year risk distant recurrence its role estimating chemotherapy benefit has b...

the evaluate the diagnostic value of image guided fine needle aspiration (fna) in breast lesions, the cytologic results of 401 patients were studied. all patients had either unpalpable masses or lesions who were hardly possible to localize by palpation and fna was performed by single radiologist under ultrasound guide in all cases. the cytologic results were divided into four categories (inconc...

background: in some verses in holy quran; 233 surat al-baghare , 15 al-ahghaf , 14 loghman and 6 al-talagh, breastfeeding, gravidity, and parity recommended to the parents and expected their children to be accountable to the parents; particularly to mothers due to tolerate of pregnancy and breastfeeding duration. methods: the case-control study included 376 patients diagnosed between      2001-...

BACKGROUND The luminal subtype of breast cancer is sensitive to anti-estrogen therapy and shows a better prognosis than that of human epidermal growth factor receptor2 (HER2)-enriched or triple-negative breast cancer. However, the luminal type of breast cancer is heterogeneous and can have aggressive clinical features. We investigated the clinical implications of single hormone receptor negativ...

Patients with triple-negative breast cancer are characterized by a poor prognosis compared with patients with other breast cancer subtypes. The angiogenesis inhibitor bevacizumab is effective in the palliative treatment of patients with triple-negative breast cancer as well as in other breast cancer subtypes. PARP inhibitors represent the first group of targeted agents to be developed under the...

Triple-negative breast cancer represents approximately 15%-20% of all newly diagnosed breast cancers, but it accounts for a disproportionate number of breast cancer-related deaths each year. Owing to the lack of estrogen, progesterone, and human epidermal growth factor receptor 2 expression, patients with triple-negative breast cancer do not benefit from generally well-tolerated and effective t...

Breast cancer is the most common malignant tumor among women. It accounts for 22% of all female cancers; more than twice the prevalence of cancer in women at any other site. Immunohistochemistry (IHC) is now the globally accepted methodology for detection of estrogen (ER) and progesterone (PR) receptors in breast carcinomas. The present study is designed for further insight into age and biology...